Beranda › Dermatitis Atopik (Eksim) › Michigan
Uji klinis Dermatitis Atopik (Eksim) di Michigan
14 studi untuk Dermatitis Atopik (Eksim) mencari peserta di lokasi di Michigan.
Kota di Michigan
Teks studi resmi (Bahasa Inggris)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- David Fivenson, MD, Dermatology, PLLC- Site Number : 8400017, Ann Arbor
- Oakland Hills Dermatology- Site Number : 8400042, Auburn Hills
- Great Lakes Research Group - Bay City- Site Number : 8400052, Bay City
- dan 3 lainnya
Menerima pesertaStudi observasional
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Troy
Menerima pesertaFase 2
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Auburn Hills
- Enveda Investigative Site, Bay City
- Enveda Investigative Site, Clinton Township
- dan 1 lainnya
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Detroit
- Investigational Site, Troy
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07003425Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Derm Research Institute, PLC, Caledonia
Menerima pesertaStudi observasional
Usia 12 hingga 89 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07645820A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Revival Research Institute, LLC, Troy
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07223697FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Revival Research Institute, LLC, Troy
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06564389A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Waterford
Menerima pesertaFase 3
6 Months – 11 Years · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Henry Ford Medical Center - New Center One /ID# 263522, Detroit
Menerima pesertaFase 3
Usia 18 hingga 63 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Michigan Center for Research Company, Clarkston
- MI Skin Innovations, Northville
- Revival Research Institute LLC, Troy
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7066, Auburn Hills
- Galderma Investigational Site 7071, Caledonia
- Galderma Investigational Site 7108, Grandville
- dan 1 lainnya
Menerima pesertaStudi observasional
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT06988605Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
- University of Michigan, Ann Arbor
Menerima pesertaSukarelawan sehat diterima
Usia 10 hingga 55 · Semua jenis kelamin · Diperbarui 25 Nov 2025 · NCT06300697Ethnic Differences in Mechanisms of Action of Dupilumab
- University of Michigan, Ann Arbor
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Nov 2025 · NCT05268107A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 24 Jan 2025 · NCT06524635Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.